ERBB2 and inflammatory breast carcinoma: Of the 364 patients who were diagnosed with nonmetastatic IBC and screened for inclusion in our study, those patients receiving neoadjuvant chemotherapy (n = 346, 95%), whose HR and HER2 statuses were available (n = 337, 93%) and who underwent surgery (n = 317, 87%) were included (Figure S1).